Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Oct 31;14(10):4184-4186.
doi: 10.21037/tlcr-2025-665. Epub 2025 Oct 29.

KRAS under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition

Markus Falk  1 , Stefanie Schatz  1 , Markus Tiemann  1 , Joachim H Ficker  2 , Wolfgang M Brueckl  2
Affiliations
Editorial

KRAS under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition

Markus Falk et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Kirsten rat sarcoma virus inhibition (KRAS inhibition); Precision oncology; exportin-1 inhibition (XPO1 inhibition); selinexor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-665/coif). J.H.F. received lecture fees from AstraZeneca, Roche and Sanofi; and fees for attending an advisory board from Roche. W.M.B. received honoraria for lectures, presentation, speakers bureaus, manuscript writing or educational events from AstraZeneca, Boehringer, Novartis, MSD, BMS, Lilly, Pfizer and Roche; received support for attending meetings and/or travel from Boehringer, Roche and AstraZeneca; participated on a data safety monitoring board or an advisory board on Astra Zeneca, Boehringer, Novartis, MSD, Lilly Pharma, BMS, and Roche; and received equipment, material, drugs, medical writing, gifts or other services from Boehringer (for medical writing). The other authors have no conflicts of interest to declare.

Comment in

Comment on

References

    1. Gao W, Jin J, Yin J, et al. KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients. Mol Carcinog 2017;56:381-8. 10.1002/mc.22501 - DOI - PubMed
    1. Zhao N, Wilkerson MD, Shah U, et al. Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer 2014;86:255-61. 10.1016/j.lungcan.2014.08.013 - DOI - PMC - PubMed
    1. Ricciuti B, Alessi JV, Elkrief A, et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D)-mutated non-small-cell lung cancer. Ann Oncol 2022;33:1029-40. 10.1016/j.annonc.2022.07.005 - DOI - PMC - PubMed
    1. Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther 2021;6:386. 10.1038/s41392-021-00780-4 - DOI - PMC - PubMed
    1. von Itzstein MS, Burns TF, Dowell JE, et al. Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 2025;31:639-48. doi: 10.1158/1078-0432.CCR-24-1722 - DOI - PMC - PubMed

LinkOut - more resources